Eli Lilly has signed a heavily…
Eli Lilly has signed a heavily backloaded agreement to license [...]
With a pair of phase 2 readouts,…
With a pair of phase 2 readouts, AstraZeneca is positioning [...]
Looking to spark an antibody-like…
Looking to spark an antibody-like revolution for RNA interference medicines, [...]
Treeline Biosciences, an…
Treeline Biosciences, an under-the-radar cancer company that has raised more [...]
Johnson & Johnson has paid $1…
Johnson & Johnson has paid $1 billion upfront to buy [...]
Incyte has struck a deal to buy a…
Incyte has struck a deal to buy a Star Therapeutics [...]
GSK’s latest hepatology…
GSK’s latest hepatology partnership is posing a less-asked question—how do [...]
Roche is paying Nurix Therapeutics…
Roche is paying Nurix Therapeutics $700 million upfront for rights [...]
Even as Zepbound fires on all…
Even as Zepbound fires on all cylinders and Foundayo gets [...]
On the heels of a strong showing…
On the heels of a strong showing for the drug [...]